Clegg 2006.

Methods	Randomized controlled trial Double blinded Multicenter (NIH Funded in the USA) Parallel group
Participants	Outpatients with symptomatic OA of the knee Country: USA N = 1583 Mean age = 58.6 years Female: 64% Male: 36%
Interventions	GH 500 mg PO TID versus chondroitin sulfate 1200 mg/day versus GH + chondroitin sulfate versus Celebrex 200 mg/day versus placebo Duration: 24 weeks
Outcomes	WOMAC pain, OMERACT‐OARSI responders, WOMAC stiffness, WOMAC function, HAQ Disability, HAQ pain, Patient global assessment, Physician's global assessment of disease status, joint swelling, effusion, usage of acetaminophen
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate